Evidence map›Paper›PMID 34169626›Full record

ArticleChembiochem : a European journal of chemical biology2021

The Innate Immune Glycoprotein Lactoferrin Represses the Helicobacter pylori cag Type IV Secretion System.

Jacky Lu, Kathryn P Haley, Jamisha D Francis, Miriam A Guevara, Ryan S Doster, Kelly M Craft, Rebecca E Moore, Schuyler A Chambers, Alberto G Delgado, Maria Blanca Piazuelo and 3 more

Open access · greenAbstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Challenges and Prospects for Eradication ofPathogens (Basel, Switzerland) · 2025
    Review
  5. Review
  6. Association of salivary lactoferrin,Frontiers in immunology · 2025
    Article
  7. Diseases (Basel, Switzerland) · 2024
    Review
  8. Antimicrobial Effects of Lactoferrin againstPathogens (Basel, Switzerland) · 2023
    Review
  9. Frontiers in microbiology · 2023
    Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Jacky LuDepartment of Medicine- Division of Infectious Diseases, Vanderbilt University Medical Center, A2200 Medical Center North, 1161 21st Avenue South, Nashville, Tennessee, 37232, USA.
Kathryn P HaleyDepartment of Biology, Grand Valley State University Allendale, Michigan, 49401, USA.
Jamisha D FrancisDepartment of Medicine- Division of Infectious Diseases, Vanderbilt University Medical Center, A2200 Medical Center North, 1161 21st Avenue South, Nashville, Tennessee, 37232, USA.
Miriam A GuevaraDepartment of Medicine- Division of Infectious Diseases, Vanderbilt University Medical Center, A2200 Medical Center North, 1161 21st Avenue South, Nashville, Tennessee, 37232, USA.
Ryan S DosterDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, 37232, USA.
Kelly M CraftDepartment of Chemistry, Vanderbilt University, SC 7300 Stevenson Science Center, 1234 Stevenson Center Lane, Nashville, Tennessee, 37235, USA.
Rebecca E MooreDepartment of Chemistry, Vanderbilt University, SC 7300 Stevenson Science Center, 1234 Stevenson Center Lane, Nashville, Tennessee, 37235, USA.
Schuyler A ChambersDepartment of Chemistry, Vanderbilt University, SC 7300 Stevenson Science Center, 1234 Stevenson Center Lane, Nashville, Tennessee, 37235, USA.
Alberto G DelgadoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, 37232, USA.
Maria Blanca PiazueloDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, 37232, USA.
Steven M DamoDepartment of Life and Physical Sciences, Fisk University, Nashville, Tennessee, 37208, USA.
Steven D TownsendDepartment of Chemistry, Vanderbilt University, SC 7300 Stevenson Science Center, 1234 Stevenson Center Lane, Nashville, Tennessee, 37235, USA.
Jennifer A GaddyDepartment of Medicine- Division of Infectious Diseases, Vanderbilt University Medical Center, A2200 Medical Center North, 1161 21st Avenue South, Nashville, Tennessee, 37232, USA.ORCID 0000-0002-2192-4224
Vanderbilt University Medical Center · USStevenson University · USGrand Valley State University · USVanderbilt University · USVA Tennessee Valley Healthcare System · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Role of Iron and B-Catenin Activation in Gastric CarcinogenesisP01CA116087 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2009 to 2026
$27.5M
Training In Cardiovascular ResearchT32HL007411 · NHLBI · VANDERBILT UNIVERSITY · PI BECKMAN, JOSHUA A · 1985 to 2020
$7.2M
Childhood Infections Research ProgramT32AI095202 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JAMES E CASSAT · 2011 to 2026
$4.2M
Chemical Biology of Infectious Diseases (CBID) Training ProgramT32AI112541 · NIAID · VANDERBILT UNIVERSITY · PI Eric P Skaar · 2015 to 2026
$4.0M
Initiative for Maximizing Student Development (IMSD) at VanderbiltT32GM139800 · NIGMS · VANDERBILT UNIVERSITY · PI RHOADES (STERLING), JULIE A, SEREZANI, C. HENRIQUE · 2021 to 2025
$3.7M
Bioorganic Approaches Toward Novel Antimicrobial Agents and ChemotherapeuticsR35GM133602 · NIGMS · VANDERBILT UNIVERSITY · PI Steven D. Townsend · 2019 to 2026
$3.0M
Determining the contribution of zinc deficiency to perinatal Group B Streptococcus infectionsR01HD090061 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ARONOFF, DAVID M, GADDY, JENNIFER A · 2017 to 2021
$2.5M
Defining the impact of zinc on Streptococcus agalactiae biofilm and colonizationK08AI151100 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DOSTER, RYAN S · 2020 to 2024
$927k
BLRD VA I01 BX005352BLRD VA IK2 BX001701Career Development IK2BX001701Childhood Infections Research 2T32AI112541-06Childhood Infections Research R35 GM133602Childhood Infections Research T32-AI095202Core ScholarshipNational Science Foundation 1400969National Science Foundation 1547757NCATS NIH HHS 5UL1TR002243-03NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR002243NCI NIH HHS P01 CA116087NCRR NIH HHS UL1 RR024975NHLBI NIH HHS T32 HL007411NIAID NIH HHS F32 AI102568NIAID NIH HHS K08 AI151100NIAID NIH HHS T32 AI095202NIAID NIH HHS T32 AI112541NICHD NIH HHS R01 HD090061NIDDK NIH HHS P30 DK058404NIGMS NIH HHS R35 GM133602NIGMS NIH HHS T32 GM139800NIH HHS GM05551NIH HHS T32 HL007411-36S1Office of Medical ResearchTissue Morphology SubcoreVAVanderbilt Institute for Clinical and Translational ResearchVanderbilt University Medical Center's Digestive Disease Research Center
6 · The paper itself

Abstract

Chronic infection with Helicobacter pylori increases risk of gastric diseases including gastric cancer. Despite development of a robust immune response, H. pylori persists in the gastric niche. Progression of gastric inflammation to serious disease outcomes is associated with infection with H. pylori strains which encode the cag Type IV Secretion System (cag T4SS). The cag T4SS is responsible for translocating the oncogenic protein CagA into host cells and inducing pro-inflammatory and carcinogenic signaling cascades. Our previous work demonstrated that nutrient iron modulates the activity of the T4SS and biogenesis of T4SS pili. In response to H. pylori infection, the host produces a variety of antimicrobial molecules, including the iron-binding glycoprotein, lactoferrin. Our work shows that apo-lactoferrin exerts antimicrobial activity against H. pylori under iron-limited conditions, while holo-lactoferrin enhances bacterial growth. Culturing H. pylori in the presence of holo-lactoferrin prior to co-culture with gastric epithelial cells, results in repression of the cag T4SS activity. Concomitantly, a decrease in biogenesis of cag T4SS pili at the host-pathogen interface was observed under these culture conditions by high-resolution electron microscopy analyses. Taken together, these results indicate that acquisition of alternate sources of nutrient iron plays a role in regulating the pro-inflammatory activity of a bacterial secretion system and present novel therapeutic targets for the treatment of H. pylori-related disease.

Indexed as

AnimalsDisease Models, AnimalEpithelial CellsGastric MucosaGerbillinaeHelicobacter InfectionsHelicobacter pyloriImmunity, InnateInterleukin-8IronLactoferrinProtein IsoformsType IV Secretion SystemsInterleukin-8IronLactoferrinProtein IsoformsType IV Secretion Systemsantimicrobialbacterial pathogenesisglycobiologyHelicobacter pylorihost-pathogen interactionsinnate immunityiron homeostasislactoferrintoxin secretionvirulence

Identifiers

PMID34169626
PMCPMC8560179
OpenAlexW3177027341

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.